Debt-to-equity of Corvus Pharmaceuticals, Inc. from 30 Sep 2016 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Corvus Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2016 to 30 Sep 2025.
  • Corvus Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 28%, a 49% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Corvus Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 28% -27% -49% 30 Sep 2025
Q2 2025 58% +38% +183% 30 Jun 2025
Q1 2025 73% +55% +306% 31 Mar 2025
Q4 2024 79% +61% +344% 31 Dec 2024
Q3 2024 54% +35% +185% 30 Sep 2024
Q2 2024 21% -0.21% -1% 30 Jun 2024
Q1 2024 18% -1.7% -8.8% 31 Mar 2024
Q4 2023 18% +0.17% +0.96% 31 Dec 2023
Q3 2023 19% +3.4% +22% 30 Sep 2023
Q2 2023 21% +7.4% +55% 30 Jun 2023
Q1 2023 20% +6.6% +50% 31 Mar 2023
Q4 2022 18% +3.9% +28% 31 Dec 2022
Q3 2022 16% +0.52% +3.5% 30 Sep 2022
Q2 2022 13% -4.4% -25% 30 Jun 2022
Q1 2022 13% -8.1% -38% 31 Mar 2022
Q4 2021 14% -10% -42% 31 Dec 2021
Q3 2021 15% -8.6% -36% 30 Sep 2021
Q2 2021 18% -1.8% -9% 30 Jun 2021
Q1 2021 21% +4% +23% 31 Mar 2021
Q4 2020 24% +9.4% +65% 31 Dec 2020
Q3 2020 24% +12% +101% 30 Sep 2020
Q2 2020 20% +9.8% +100% 30 Jun 2020
Q1 2020 17% +8.8% +105% 31 Mar 2020
Q4 2019 15% +6.8% +88% 31 Dec 2019
Q3 2019 12% +3.2% +37% 30 Sep 2019
Q2 2019 9.9% +0.16% +1.6% 30 Jun 2019
Q1 2019 8.4% -1.9% -18% 31 Mar 2019
Q4 2018 7.8% -2.4% -23% 31 Dec 2018
Q3 2018 8.6% +0.16% +1.9% 30 Sep 2018
Q2 2018 9.7% +2.9% +43% 30 Jun 2018
Q1 2018 10% +5.1% +100% 31 Mar 2018
Q4 2017 10% +6% +146% 31 Dec 2017
Q3 2017 8.4% +3.6% +74% 30 Sep 2017
Q2 2017 6.8% 30 Jun 2017
Q1 2017 5.1% 31 Mar 2017
Q4 2016 4.1% 31 Dec 2016
Q3 2016 4.9% 30 Sep 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.